ChitogenX Inc. (CHGX.CN)

0.0450 0.0000 (0.00%) At close: 09:49AM EDT

ChitogenX Inc.

16667 Hymus Boulevard
Kirkland, QC H9H 4R9
Canada
514-261-4735
https://www.chitogenx.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Pierre Laurin B.Sc.Pharm., M.Sc.	Interim CEO & Chairman	N/A	N/A	1961
Mr. Luc Mainville M.B.A, M.B.A.	Senior VP & CFO	179.8k	N/A	1964
Mr. Guy-Paul Allard	VP of Legal Affairs & Corporate Secretary	N/A	N/A	N/A
Dr. Jonathan Sackier	Senior Vice President of Medical Affairs	226.8k	N/A	N/A
Mr. Frederic Dumais	Director of Communications & Investor Relations	N/A	N/A	N/A
Benedek Simo	Controller	N/A	N/A	N/A

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.

Description

ChitogenX Inc., an orthopaedic and sports medicine biologics company, engages in the research and development of novel therapeutic soft tissue repair technologies to enhance the success rate of orthopaedic and sports medicine surgeries in Canada. It develops Ortho-R, a biopolymer for rotator cuff repair; and Ortho-M, a biopolymer for meniscus repair. The company was formerly known as Ortho Regenerative Technologies Inc. and changed its name to ChitogenX Inc. in September 2022. ChitogenX Inc. was incorporated in 2015 and is headquartered in Kirkland, Canada.

Corporate Governance

ChitogenX Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.